Ge Long Hui·2026-02-03 11:12Core Viewpoint - Kangfang Biopharma has signed an exclusive commercialization rights agreement with Jichuan Pharmaceutical, granting Jichuan the exclusive rights to commercialize the drug Yixinning (Inusimab Injection) in mainland China, excluding Hong Kong, Macau, and Taiwan [1] Group 1: Agreement Details - The agreement involves Kangfang Biopharma's indirect wholly-owned subsidiary, Zhongshan Kangfang Biopharma Co., Ltd., and Jichuan Pharmaceutical's subsidiaries [1] - Kangfang Biopharma will receive a total of RMB 80 million (including tax) as a licensing fee from Jichuan Pharmaceutical, along with potential milestone payments of up to RMB 10 million (including tax) [1] - Jichuan Pharmaceutical will be responsible for the commercialization and sales of Yixinning in the authorized market [1]